Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Cancer Res. 2015 Apr 15;75(8):1675–1681. doi: 10.1158/0008-5472.CAN-14-2852

Figure 4. Ibrutinib has a significant therapeutic impact as monotherapy and in combination with standard of care. Two independent experiments were conducted to determine the survival effect of ibrutinib.

Figure 4

A, p53ER/ER;LSLKRasG12D;Pdx1-cre mice were treated with ibrutinib (n = 14) or vehicle control (n = 13) starting from 8 weeks of age. Ibrutinib alone confers survival advantage to the treated animals (P = 0.030, log-rank test). B, p53ER/ER;LSLKRasG12D;Pdx1-cre mice were treated with gemcitabine (n = 8) or with a combination of gemcitabine and ibrutinib (n = 9), starting from 8 weeks of age. The addition of ibrutinib to standard of care improves animal survival (P = 0.025, log-rank test).